Background Finding a specific agent is useful for early detection of tumor. Angiotensin II type 1 receptor (AT1R) was reported to be elevated in a variety of tumors and participate in tumor progression. The aim of our study was to evaluate whether 131I-anti-AT1R monoclonal antibody (mAb) is an efficient imaging reporter for the detection of hepatocellular carcinoma. Methodology/Principal Findings AT1R mAb or isotype IgG was radioiodinated with 131I and the radiochemical purity and stability of the two imaging agents and the affinity of 131I-anti-AT1R mAb against AT1R were measured. 3.7 MBq 131I-anti-AT1R mAb or isotype 131I-IgG was intravenously injected to mice with hepatocellular carcinoma through tail vein, and then the whole-body autoradiography and biodistribution of the two imaging agents and the pharmacokinetics of 131I-anti-AT1R mAb were studied. 131I-anti-AT1R mAb and 131I-IgG were successfully radioiodinated and both maintained more stable in serum than in saline. The 131I-anti-AT1R mAb group showed much clearer whole-body images for observing hepatocellular carcinoma than the 131I-IgG group. The biodistributions of the two imaging agents suggested that hepatocellular carcinoma tissue uptook more 131I-anti-AT1R mAb than other tissues (%ID/g = 1.82±0.40 and T/NT ratio = 7.67±0.64 at 48 h), whereas hepatocellular carcinoma tissue did not selectively uptake 131I-IgG (%ID/g = 0.42±0.06 and T/NT ratio = 1.33±0.08 at 48 h). The pharmacokinetics of 131I-anti-AT1R mAb was in accordance with the two-compartment model, with a rapid distribution phase and a slow decline phase. These results were further verified by real-time RT-PCR, immunohistochemistry staining and Western blot. Conclusions/Significance 131I-anti-AT1R mAb may be a potential target for early detection of tumor.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
[3]
Singal A, Volk ML, Waljee A, Salgia R, Higgins P, et al. (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30: 37–47.
[4]
Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, et al. (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138: 493–502.
[5]
Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, et al. (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101: 513–523.
[6]
Liang T, Zhang C, Song J, Jiang S, Hao J, et al. (2011) Evaluation of 131I-anti-MIF mAb as a reporter for allograft rejection. Clin Immunol 139: 40–47.
[7]
Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, et al. (2001) Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 14: 1349–1356.
[8]
Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158: 1633–1637.
[9]
Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T (2004) Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 190: 1258–1263.
[10]
Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination, Clin Cancer Res. 11: 2686–2694.
[11]
Won SM, Park YH, Kim HJ, Park KM, Lee WJ (2006) Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med 38: 525–534.
[12]
Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, et al. (2007) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67: 41–49.
[13]
Zhang C, Hou G, Liang T, Song J, Qu L, et al. (2007) A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection. J Cell Mol Med 13: 4077–4083.
[14]
Zhao Q, Yan P, Wang RF, Zhang CL, Li L, et al. (2013) A novel 99 mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study. PLoS One 8: e61043.
[15]
Bonde MM, Hansen JT, Sanni SJ, Hauns？ S, Gammeltoft S, et al. (2010) Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. PLoS One 5: e14135.
[16]
Wu C, Wei J, Tian D, Feng Y, Miller RH, et al. (2008) Molecular Probes for Imaging Myelinated White Matter in CNS. J Med Chem 51: 6682–6688.
[17]
Jonathan S Wall, Stephen J Kennel, Angela Williams, Tina Richey, Alan Stuckey, et al. (2012) AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils. PLoS One 7: e52686.
[18]
Ozeki K, Tanida S, Morimoto C, Inoue Y, Mizoshita T, et al. (2013) Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One 8: e56770.
[19]
Khakoo AY, Sidman RL, Pasqualini R, Arap W (2008) Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 68: 9112–9115.
[20]
Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674–687.
[21]
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55–76.
[22]
Heffelfinger SC (2007) The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 13: 1215–1229.
Tahmasebi M, Barker S, Puddefoot JR, Vinson GP (2006) Localisation of renin-angiotensin system (RAS) components in breast. Br J Cancer 95: 67–74.
[25]
Lau ST, Leung PS (2011) Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 11: 412–420.
[26]
Koh SL, Ager EI, Christophi C (2010) Liver regeneration and tumour stimulation: implications of the rennin-angiotensin system. Liver Int 30: 1414–1426.
[27]
Dzau VJ, Mukoyama M, Pratt RE (1994) Molecular biology of angiotensin receptors: target for drug research? J Hypertens Suppl 12: S1–S5.
[28]
Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, et al. (2005) Angiotensin type 1a receptor signaling dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271–279.
